Gastroenterology Research and Practice / 2014 / Article / Tab 1

Review Article

Targeting Angiogenesis and Tumor Microenvironment in Metastatic Colorectal Cancer: Role of Aflibercept

Table 1

Bevacizumab, aflibercept, and regorafenib are antiangiogenic drugs currently approved for mCRC treatment. These drugs have proved successful for the clinical treatment of various types of cancer and their mechanism of action results different affecting a variable range of cell types and signaling within tumor microenvironment.

Drug Indication Mechanism of action

Bevacizumab First-/second-line mCRC plus CT MoAb binding VEGF-A
Aflibercept Second-line mCRC plus FOLFIRI VEGF decoy binding VEGF-A, VEGF-B, and PlGF
Regorafenib Third-line mCRC as single agent Multikinase inhibitor of RTKI of VEGFR-2 and -3, TIE-2, PDGFR, FGFR, RET, and c-kit